Binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosaminoglycans

Thrombosis Research

Volumn 84, Issue 4, 1996, Pages 267-278

  Iversen, Nina ^a   Sandset, Per Morten ^b   Abildgaard, Ulrich ^a   Torjesen, Peter A ^a  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

cell binding; endothelial cells; glycosaminoglycans; tissue factor; tissue factor pathway inhibitor

Indexed keywords

DERMATAN SULFATE; ENOXAPARIN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTICOAGULANTS; CHLORATES; DERMATAN SULFATE; ENDOTHELIUM, VASCULAR; FACTOR XA; FIBRINOLYTIC AGENTS; GLYCOSAMINOGLYCANS; HEPARIN; HEPARITIN SULFATE; HUMANS; KINETICS; LIPOPROTEINS; TIME FACTORS;

EID: 0030588626     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(96)00186-7     Document Type: Article

References (45)

1. Rapaport SI Inhibition of factor VIIa/TF-induced blood coagulation: With particular emphasis upon a factor Xa-dependent inhibitory mechanism. Blood. 73:1989;359-365.
2. Broze GJ Jr., Girard TJ, Novotny WF Regulation of blood coagulation by a multivalent Kunitz-type inhibitor. Biochemistry. 29:1990;7539-7546.
3. Sandset PM, Warm-Cramer BJ, Rao LVM, Maki SL, Rapaport SI Depletion of extrisic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with TF: Evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA. 88:1991;708-712.
4. Østerud B, Rapaport SI Activation of factor X by the reaction product of tissue factor and factor. VII: Additional pathway initiating blood coagulation Proc Natl Acad Sci USA. 74:1977;5260-5264.
5. Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard TJ, Miletich JP The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood. 71:1988;335-343.
6. Warm Cramer BJ, Rao LVM, Maki SL, Rapaport SI Modifications of extrisic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: Evidence for a two-step model of inhibition. Thromb Haemost. 60:1988;453-456.
7. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ Jr. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature. 338:1989;518-520.
8. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consist of three tandem Kunitz-type inhibitory domains. J Biol Chem. 263:1988;6001-6004.
9. Nordfang O, Bjørn SE, Valentin S, Nielsen LS, Wildgoose P, Beck U, Hedner U The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry. 30:1991;10371-10376.
10. Wesselschmidt R, Likert K, Girard T, Wun TC, Broze GJ Jr. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of Factor Xa. Blood. 79:1992;2004-2010.
11. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP Cultured normal human hepatocytes do not synthesize lipoprotein - associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA. 87:1990;8869-8873.
12. Werling RW, Zacharski LR, Kisiel W, Bajaj SP, Memoli VA, Rousseau SM Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemostas. 69:1993;366-369.
13. Sandset PM, Abildgaard U, Larsen ML Heparin induces release of extrinsic pathway inibitor (EPI). Thromb Res. 50:1988;803-813.
14. Novotny WF, Palmier M, Wun TC, Broze GJ Jr., Miletich JP Purification and properties of heparin releasable lipoprotein-associated inhibitor. Blood. 78:1991;394-400.
15. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Purification and characterization of the lipoprotein-associated coagulation inhibitor from normal plasma. J Biol Chem. 264:1989;18832-18837.
16. Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordoy A Tissue factor pathxay inhibitor and lipoproteins: Evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb. 14:1994;223-229.
17. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Platelets secrete a coagulation inhibitor functionally and antigenically simular to the lipoprotein associated coagulation inhibitor. Blood. 71:1988;2020-2025.
18. Hansen JB, Huseby KR, Huseby NE, Sandset PM, Hanssen TA, Nordoy A Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoporteinemia. Arterioscler Thromb Vasc Biol. 15:1995;879-885.
19. Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis. 2:1991;713-721.
20. Wun TC Lipoprotein associated coagulation inhibitor (LACI) is a cofactor for heparin synergistic anticoagulant action between LACI and sulfated polysaccharide. Blood. 79:1992;430-438.
21. Marcum JA, Atha DH, Fritze L, Nawroth P, Stern D, Rosenberg RD Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulphate proteoglycan. J Biol Chem. 261:1986;7507-7517.
22. Castillo CJ, Colburn P, Buonassisi V Characterization and N-terminal sequence of a heparan sulphate proteoglycan synthesized by endothelial cells in culture. Biochem J. 247:1987;687-693.
23. Valentin S, Larnkjer A, Ostergaard P, Nielsen JI, Nordfang O Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res. 75:1994;173-183.
24. Petersen JGL, Meyn G, Rasmussen JS, Petersen J, Bjørn SE, Jonassen I, Christiansen L, Nordfang O Characterization of human tissue factor pathway inhibitor TFPI expreesed in saccharomyces cerevisiae. J Biol Chem. 268:1993;13344-13351.
25. Pedersen AH, Nordfang O, Norris F, Wiberg FC, Christensen PM, Møller KB, Meidal-Pedersen J, Bech TC, Norris K, Hedner U, Kisiel W Recombinant human extrinsic pathway inhibitor. J Biol Chem. 265:1990;16786-16793.
26. Fraker PJ, Speck JC Protein and cell-membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a, 6a-diphenylglycoluril. Biochem Biophys Res Commun. 80:1978;849-857.
27. Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Ødegaard OR Chromogenic substrate assay of extrisic pathway inhibitor (EPI): Levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis. 2:1991;425-433.
28. Jaffe EA, Nachman RL, Becker CG, Minick CR Culture of human endothelial cells derived from umbilical veins. J Clin Invest. 52:1973;2745-2756.
29. Edgell CJ, McDonald CC, Graham JB Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA. 80:1983;3734-3737.
30. Beretz A, Freyssinet JM, Gauchy J, Schmitt DA, Klein-Soyer C, Edgell C-JS, Cazenave JP Stability of the thrombin-thrombomodulin complex on the surface of endothelial cells from human saphenous vein or from the cell line Ea·hy 926. Biochem J. 259:1989;35-40.
31. Emeis JJ, Edgell C-JS Fibrinolytic properties of a human endothelial hybrid cell line (Ea·hy 926). Blood. 64:1986;699-705.
32. Van Ooost BA, Edgell C-JS, Hay CW, MacGillivray RTA Isolation of a human von Willibrand factor cDNA from the hybrid endothelial cell line Ea·hy 926. Biochem Cell Biol. 64:1986;699-705.
33. Radlig version 4 of Kinetic, Ebda, Ligand, Lowry; A collection of radioligand binding analysis programs for IBM PC, Biosoft, Cambridge, U.K, 1994.
34. Warshawsky I, Broze GJ Jr., Schwarzt AL The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci USA. 91:1994;6664-6668.
35. Callander NS, Rao LVM, Nordfang O, Sandset PM, Warn-Cramer B, Rapaport SI Mechanism of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. J Biol Chem. 267:1992;876-882.
36. Warshawsky I, Bu G, Mast A, Saffitz JE, Broze GJ Jr., Schwartz AL The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest. 95:1995;1773-1781.
37. Kjellen L, Lindahl U Proteoglycans: structures and interactions. Annu Rev Biochem. 60:1991;443-475.
38. Wesselschmidt R, Likert K, Huang ZF, MacPhail L, Broze GJ Jr. Structural requirements for tissue factor pathway inhibitor interactions with Factor Xa and heparin. Blood Coagul Fibrinolysis. 4:1993;661-669.
39. Enjyoji K, Miayata T, Kamikubo Y, Kato H Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site. Biochemistry. 34:1995;5725-5735.
40. Yamagata T, Saito H, Habuchi O, Suzuki S Purification and properties of bacterial chondroitinases and chondrosulfatases. J Biol Chem. 243:1968;1523.
41. Linker A, Hovingh P Heparinase and heparitinase from flavobacteria. Methods in Enzymol. 28:1972;902-911.
42. Olwin BB, Rapraeger A Repression of myogenic differentiation by aFGF, bFGF, and K-FGF is dependent on cellular heparan sulphate. J Cell Biol. 118:1992;631-639.
43. Sevinsky JR, Rao LVM, Ruf M Ligand-induced protease receptor translocation into caveolae: A mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol. 133:1996;293-304.
44. Zitoun D, Bara L, Bloch MF, Samana MM Plasma TFPI activity after intravenous injection of pentasaccharide (PS) and unfractionated heparin in rabbits. Thromb Res. 75:1994;577-580.
45. Lindahl AK, Sandset PM, Abildgaard U The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis. 3:1992;439-449.